Navigation Links
Research identifies type of vaccine that holds promise in protecting against TB
Date:10/19/2008

ST. LOUIS -- Researchers are one step closer to finding a vaccine that better protects against tuberculosis. An investigational vaccine for TB tested at Saint Louis University appears likely to offer significantly better protection against the potentially fatal disease than the one in current use.

"Not only was it as safe as the standard vaccine, it induced a better immune response, which suggests it will be more effective at protecting against tuberculosis," said Daniel Hoft, M.D., Ph.D., director of the division of immunobiology at Saint Louis University School of Medicine and lead author of the study.

The investigational vaccine is made from a weakened TB germ from one of the strains of the current tuberculosis vaccine, which was created more than 75 years ago. The new "recombinant" vaccine uses an antigen a secreted protein from a virulent strain of tuberculosis to help focus the immune system on blocking aggressive and deadly TB organisms.

In this phase I clinical trial, researchers vaccinated a total of 35 study participants. The standard TB vaccine -- called Bacille Calmette-Gurin (BCG) -- was given to 17 study participants, and 18 study participants received the investigational recombinant BCG vaccine.

Researchers compared five immune functions induced by the vaccines and found that the investigational vaccine induced more powerful responses that are important for protection against tuberculosis. The investigational vaccine also was safe and well tolerated.

The research demonstrated that the concept of using a recombinant vaccine holds promise in being able to better protect people from tuberculosis. This vaccine will not be tested further because it uses an antibiotic resistant gene that scientists want to keep out of the environment. However research in this area will continue as scientists test a similar recombinant BCG vaccine that expresses the same and additional key TB antigens that is expected to be even more potent than the one just studied and does not include the antibiotic resistant gene, Hoft said.

"A new vaccine theoretically could not only protect against the overwhelming growth of TB organisms, but could kill residual organisms after a person has become infected. That's the hope," Hoft said.

It's critical to find a better vaccine, Hoft said. Tuberculosis strikes developing nations hardest, infecting one in three people worldwide. Nearly 8 million new cases of TB develop each year, and 2 million die from the infectious disease.

"These staggering statistics persist despite the availability of a tuberculosis vaccine," Hoft said. "New vaccines are urgently needed to reduce this immense burden of TB."

The World Health Organization recommends the current BCG vaccine for infants in developing countries shortly after they are born. The vaccine induces partial protection, and vaccinated children who contract a tuberculosis infection have a less severe illness. The current vaccine is about 70 percent protective against deaths or meningitis from tuberculosis and about 50 percent protective against pulmonary tuberculosis.


'/>"/>

Contact: Nancy Solomon
solomonn@slu.edu
314-977-8017
Saint Louis University
Source:Eurekalert

Related biology news :

1. Researchers identify Achilles heel of common childhood tumor
2. Waste from gut bacteria helps host control weight, UT Southwestern researchers report
3. Salk researchers successfully reprogram keratinocytes attached to a single hair
4. Scripps research team sheds light on immune system suppression
5. FSU researchers discovery leads to $1.5 million grant, potential new treatment of liver fibrosis
6. MU brain imaging center provides research for autism, schizophrenia and Parkinsons disease
7. Cost-effective farm waste-to-energy technology focus of research
8. Alzheimers disease research attracts first partner
9. NARSAD announces 2008 Prizes for Outstanding Achievement in Research on Mental Health Disorders
10. Researchers identify promising gene target for neuroblastoma therapy
11. Salk researcher Terry Sejnowski elected to Institute of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia ... be hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” ... pathology adoption best practices and how Proscia improves lab economics and realizes an ...
(Date:10/11/2017)... Georgia (PRWEB) , ... October 11, 2017 , ... Disappearing ... taking the lives of over 5.5 million people each year. Especially those living in ... greenovative startup Treepex - based in one of the most pollution-affected countries globally - ...
(Date:10/10/2017)... ... 10, 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, ... The bold new look is part of a transformation to increase awareness, appeal ... growth period. , It will also expand its service offering from its signature gourmet ...
(Date:10/10/2017)... ... 2017 , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on ... DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of ...
Breaking Biology Technology: